Display options
Cite
Pabst T, Kortz L, Fiedler GM, et al. The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features. BBA Clin. 2017;7:105-114doi: 10.1016/j.bbacli.2017.03.002.
Pabst, T., Kortz, L., Fiedler, G. M., Ceglarek, U., Idle, J. R., & Beyoğlu, D. (2017). The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features. BBA clinical, 7105-114. https://doi.org/10.1016/j.bbacli.2017.03.002
Pabst, Thomas, et al. "The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features." BBA clinical vol. 7 (2017): 105-114. doi: https://doi.org/10.1016/j.bbacli.2017.03.002
Pabst T, Kortz L, Fiedler GM, Ceglarek U, Idle JR, Beyoğlu D. The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features. BBA Clin. 2017 Mar 08;7:105-114. doi: 10.1016/j.bbacli.2017.03.002. eCollection 2017 Jun. PMID: 28331812; PMCID: PMC5357680.
Copy Download .nbib Format: NLM
Share it on

BBA Clin. 2017 Mar 08;7:105-114. doi: 10.1016/j.bbacli.2017.03.002. eCollection 2017 Jun.

The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features.

BBA clinical

Thomas Pabst, Linda Kortz, Georg M Fiedler, Uta Ceglarek, Jeffrey R Idle, Diren Beyoğlu

Affiliations

  1. Department of Medical Oncology, Inselspital Bern, Switzerland.
  2. Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Germany.
  3. Institute of Clinical Chemistry, Inselspital Bern, Switzerland.
  4. Hepatology Research Group, Department of Clinical Research, University of Bern, Switzerland.

PMID: 28331812 PMCID: PMC5357680 DOI: 10.1016/j.bbacli.2017.03.002

Abstract

BACKGROUND: Early studies established that certain lipids were lower in acute myeloid leukemia (AML) cells than normal leukocytes. Because lipids are now known to play an important role in cell signaling and regulation of homeostasis, and are often perturbed in malignancies, we undertook a comprehensive lipidomic survey of plasma from AML patients at time of diagnosis and also healthy blood donors.

METHODS: Plasma lipid profiles were measured using three mass spectrometry platforms in 20 AML patients and 20 healthy blood donors. Data were collected on total cholesterol and fatty acids, fatty acid amides, glycerolipids, phospholipids, sphingolipids, cholesterol esters, coenzyme Q10 and eicosanoids.

RESULTS: We observed a depletion of plasma total fatty acids and cholesterol, but an increase in certain free fatty acids with the observed decline in sphingolipids, phosphocholines, triglycerides and cholesterol esters probably driven by enhanced fatty acid oxidation in AML cells. Arachidonic acid and precursors were elevated in AML, particularly in patients with high bone marrow (BM) or peripheral blasts and unfavorable prognostic risk. PGF2α was also elevated, in patients with low BM or peripheral blasts and with a favorable prognostic risk. A broad panoply of lipid classes is altered in AML plasma, pointing to disturbances of several lipid metabolic interconversions, in particular in relation to blast cell counts and prognostic risk.

CONCLUSIONS: These data indicate potential roles played by lipids in AML heterogeneity and disease outcome.

GENERAL SIGNIFICANCE: Enhanced catabolism of several lipid classes increases prognostic risk while plasma PGF2α may be a marker for reduced prognostic risk in AML.

Keywords: 12-HEPE, 12-hydroxy-5Z,8Z,10E,14Z,17Z-eicosapentaenoic acid; 12-LOX, 12-lipoxygenase; 2HG, (R)-2-hydroxyglutarate; 2OG, 2-oxoglutarate; 8,9-DHET, 8,9-dihydroxy-5Z,11Z,14Z-eicosatrienoic acid; AA, arachidonic acid; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Acute myeloid leukemia; Blast cell number; CE, cholesterol ester; CML, chronic myelogenous leukemia; CPT1a, carnitine palmitate transferase 1a; Cer, ceramide; CoQ10, coenzyme Q10; DG, diacylglycerol; DGLA, dihomo-γ-linoleic acid; DIC, disseminated intravascular coagulation; EPA, eicosapentaenoic acid (20:5;5Z,8Z,11Z,14Z,17Z); ESI-, electrospray ionization negative mode; ESI +,  electrospray ionization positive mode; Eicosanoids; FAA, fatty acid amide; FAB, French-American-British classification; FAME, fatty acid methyl ester; FAO, fatty acid oxidation; FLC-QqLIT-MS, fast liquid chromatography-quadrupole linear ion-trap mass spectrometry; Fatty acids; GCMS, gas chromatography–mass spectrometry; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; Lipidomics; MG, monoacylglycerol; MRM, multiple reactions monitoring; MUFA, monounsaturated fatty acid; OPLS-DA, orthogonal PLS-DA; PC, phosphatidylcholine; PCA, principal components analysis; PE, phosphatidylethanolamine; PGE2, prostaglandin E2; PGF1α, prostaglandin 1α; PGF2α, prostaglandin F2α; PGH2, prostaglandin H2; PLS-DA, projection to latent structures-discriminant analysis; POEA, palmitoleoyl ethanolamide; PUFA, polyunsaturated fatty acid; Prognostic risk; SCD1, stearoyl CoA desaturase 1; SM, sphingomyelin; TG, triacylglycerol (triglyceride); TxA2, thromboxane A2; TxB2, thromboxane B2; UPLC-ESI-QTOFMS, ultraperformance liquid chromatography-electrospray ionization-quadrupole time-of-flight mass spectrometry; mPGES-1, microsomal prostaglandin E synthase-1

References

  1. Prostaglandins Leukot Essent Fatty Acids. 1992 Sep;47(1):1-12 - PubMed
  2. Pharmacogenomics. 2017 Feb;18(3):235-244 - PubMed
  3. J Lipid Res. 2014 Nov;55(11):2309-19 - PubMed
  4. Am J Physiol. 1982 Jun;242(6):G582-7 - PubMed
  5. Prostaglandins Other Lipid Mediat. 2011 Apr;94(3-4):81-7 - PubMed
  6. Nat Genet. 1999 Aug;22(4):347-51 - PubMed
  7. Eur J Haematol. 2007 Dec;79(6):468-76 - PubMed
  8. Blood. 2015 Oct 15;126(16):1874-5 - PubMed
  9. Clin Cancer Res. 2009 Jun 1;15(11):3705-15 - PubMed
  10. Br J Haematol. 1976 Aug;33(4):451-8 - PubMed
  11. Ann Intern Med. 1985 Oct;103(4):620-5 - PubMed
  12. J Proteome Res. 2016 Jul 1;15(7):2228-35 - PubMed
  13. Cancer Biol Med. 2016 Mar;13(1):41-54 - PubMed
  14. Mol Genet Metab. 1999 Feb;66(2):91-9 - PubMed
  15. Biochim Biophys Acta. 2000 Jun 26;1486(1):128-44 - PubMed
  16. Nat Genet. 1999 Aug;22(4):336-45 - PubMed
  17. Nat Rev Cancer. 2013 Apr;13(4):227-32 - PubMed
  18. Int J Radiat Biol. 2011 Apr;87(4):360-71 - PubMed
  19. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10347-52 - PubMed
  20. Addict Biol. 2013 Nov;18(6):955-69 - PubMed
  21. J Lipid Res. 1979 Sep;20(7):908-11 - PubMed
  22. Biofactors. 2005;25(1-4):31-41 - PubMed
  23. Agents Actions. 1987 Aug;21(3-4):397-9 - PubMed
  24. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1420-7 - PubMed
  25. Oncogene. 2003 Oct 20;22(47):7537-52 - PubMed
  26. J Biol Chem. 1996 Mar 22;271(12 ):6758-65 - PubMed
  27. Agents Actions. 1987 Aug;21(3-4):400-2 - PubMed
  28. Iran J Ped Hematol Oncol. 2014;4(1):5-10 - PubMed
  29. Antioxid Redox Signal. 2000 Summer;2(2):263-75 - PubMed
  30. Nutrition. 2000 Nov-Dec;16(11-12):1116-8 - PubMed
  31. J Biol Chem. 1993 Aug 25;268(24):18128-35 - PubMed
  32. Gan. 1982 Apr;73(2):175-83 - PubMed
  33. Best Pract Res Clin Haematol. 2015 Jun-Sep;28(2-3):90-7 - PubMed
  34. Mediators Inflamm. 1998;7(2):79-84 - PubMed
  35. J Clin Invest. 2010 Jan;120(1):142-56 - PubMed
  36. Eur J Pharmacol. 2012 Jun 5;684(1-3):102-7 - PubMed
  37. Br J Pharmacol. 2016 Apr;173(7):1116-27 - PubMed
  38. Clin Chim Acta. 2015 Apr 15;444:43-9 - PubMed
  39. Oncol Rep. 2012 Aug;28(2):714-20 - PubMed
  40. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 15;927:209-13 - PubMed
  41. J Lipid Res. 1967 Jul;8(4):321-7 - PubMed
  42. Leukemia. 2002 Nov;16(11):2292-301 - PubMed
  43. Cancer Res. 2011 Nov 1;71(21):6590-600 - PubMed
  44. J Viral Hepat. 2015 Jul;22(7):617-24 - PubMed
  45. Blood. 2015 Oct 15;126(16):1925-9 - PubMed
  46. Apoptosis. 2015 Aug;20(8):1099-108 - PubMed
  47. J Cell Sci. 1976 Jan;20(1):199-206 - PubMed
  48. Cancer. 2007 Jul 1;110(1):96-102 - PubMed
  49. Exp Hematol. 2007 Dec;35(12):1793-800 - PubMed
  50. Br J Haematol. 1998 Jun;101(4):728-36 - PubMed
  51. Pharmacol Ther. 2008 Apr;118(1):18-35 - PubMed
  52. Cancer Res. 1969 Jan;29(1):251-7 - PubMed
  53. Curr Cardiovasc Risk Rep. 2014 Dec 1;8(12):null - PubMed
  54. BBA Clin. 2015 Jul 23;4:59-68 - PubMed

Publication Types